HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023
Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market: About this market
Technavio’s HER2 inhibitors market analysis considers sales from both monotherapy and combination therapy. Our analysis also considers the sales of HER2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the presence of blockbuster drugs and fewer side-effects will play a significant role in the monotherapy segment to maintain its market position. Also, our global HER2 inhibitors market report looks at factors such as the high prevalence of breast cancer and gastric cancer, recent approvals, and growing awareness about breast cancer. However, uncertainties in the introduction of Herceptin biosimilars, availability of alternative treatment options, and side effects of HER2 inhibitors may hamper the growth of the HER2 inhibitors industry over the forecast period.
Global HER2 Inhibitors Market: Overview
High prevalence of breast cancer and gastric cancer
HER2 regulates cell growth, survival, and differentiation through multiple signal transduction pathways. Owing to the overexpression of HER2, the prevalence of several cancers including breast cancer, gastric and ovarian cancer is increasing. As there is a significant unmet need for effective HER2 inhibitors with fewer side-effects, pharmaceutical companies have significant scope for growth. This will lead to the expansion of the global HER2 inhibitors market at a CAGR of almost 9% during the forecast period.
Patient assistance programs
HER2 inhibitors are available at high costs, making it difficult for patients to purchase them. Thus, pharmaceutical sponsors are providing several patient assistance programs to reduce the cost burden, thus increasing patient adherence to HER2 inhibitors. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global HER2 inhibitors market during the forecast period 2019-2023, click here.
With the presence of several major players, the global HER2 inhibitors market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 inhibitors manufacturers, that include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc.
Also, the HER2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook